Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

Clinical trial NCT06762782 · RECRUITING

Trial details

NCT number: NCT06762782
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation

Start date: 2025-02-01
Primary completion: 2027-10-01
Enrollment: 276

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.